Axel Vater

Company: APTARION biotech AG

Job title: Founder & Chief Scientific Officer

Seminars:

C5a Neutralization by Clinical-Stage AON-D21 Shows Promise in Animal Models from Pneumonia to Lung Cancer 2:00 pm

AON-D21 is a mirror-image (L-)RNA aptamer that binds C5a and inhibits its signaling on C5aR1 and C5aR2 Analyze preclinical data showing that C5a-inhibition with AON-D21 is efficacious in diseases such as pneumonia, sepsis and lung cancer AON-D21 has passed Phase 1 First in Human studies and will enter a Phase 2 Proof of Concept trial…Read more

day: Day Two